American Century Companies Inc. lowered its stake in shares of Medifast (NYSE:MED) by 25.4% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 219,101 shares of the specialty retailer’s stock after selling 74,672 shares during the period. American Century Companies Inc. owned approximately 1.82% of Medifast worth $20,475,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of MED. Convergence Investment Partners LLC bought a new position in Medifast during the 4th quarter valued at about $494,000. Schwab Charles Investment Management Inc. lifted its stake in Medifast by 3.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 46,693 shares of the specialty retailer’s stock valued at $3,260,000 after acquiring an additional 1,441 shares during the period. Acadian Asset Management LLC increased its position in shares of Medifast by 1.7% during the 4th quarter. Acadian Asset Management LLC now owns 458,674 shares of the specialty retailer’s stock valued at $32,019,000 after purchasing an additional 7,489 shares during the last quarter. First Quadrant L P CA increased its position in shares of Medifast by 5.9% during the 4th quarter. First Quadrant L P CA now owns 12,388 shares of the specialty retailer’s stock valued at $865,000 after purchasing an additional 693 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Medifast during the 4th quarter valued at about $2,417,000. Institutional investors and hedge funds own 86.64% of the company’s stock.

Several equities research analysts have recently commented on the stock. DA Davidson upped their price target on shares of Medifast to $135.00 and gave the company a “buy” rating in a research report on Friday, May 4th. Sidoti reaffirmed a “neutral” rating on shares of Medifast in a research report on Thursday, April 19th. ValuEngine raised shares of Medifast from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 2nd. Finally, Zacks Investment Research raised shares of Medifast from a “hold” rating to a “strong-buy” rating and set a $97.00 price target for the company in a research report on Saturday, March 10th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. Medifast presently has a consensus rating of “Buy” and an average price target of $95.67.

In related news, Director Charles P. Connolly sold 7,500 shares of the stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $89.31, for a total value of $669,825.00. Following the completion of the sale, the director now directly owns 40,342 shares of the company’s stock, valued at approximately $3,602,944.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael C. Macdonald sold 20,000 shares of the stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $84.45, for a total transaction of $1,689,000.00. Following the completion of the sale, the director now directly owns 334,188 shares of the company’s stock, valued at $28,222,176.60. The disclosure for this sale can be found here. Insiders have sold a total of 35,500 shares of company stock valued at $3,086,425 in the last ninety days. Insiders own 6.47% of the company’s stock.

Medifast opened at $132.91 on Friday, according to MarketBeat. Medifast has a 52 week low of $128.31 and a 52 week high of $129.85. The stock has a market cap of $1.55 billion, a PE ratio of 58.04, a price-to-earnings-growth ratio of 2.35 and a beta of 0.25.

Medifast (NYSE:MED) last released its quarterly earnings results on Thursday, May 3rd. The specialty retailer reported $1.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.86 by $0.15. Medifast had a net margin of 10.26% and a return on equity of 31.11%. The firm had revenue of $98.60 million during the quarter, compared to analyst estimates of $89.23 million. During the same quarter in the prior year, the firm earned $0.36 EPS. The business’s revenue for the quarter was up 39.7% compared to the same quarter last year. sell-side analysts expect that Medifast will post 3.65 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, May 8th. Stockholders of record on Friday, March 30th were given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a dividend yield of 1.44%. The ex-dividend date of this dividend was Wednesday, March 28th. Medifast’s payout ratio is currently 83.84%.

Medifast Profile

Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.

Institutional Ownership by Quarter for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.